Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study

S Maury; M Rosenzwajg; R Redjoul; A Marcais; A Xhaard; M Cherai; L Cabanne; G Churlaud; F Suarez; G Socié; L Gregoire; K Debbache; C Bernard; J-L Beaumont; N Azar; O Boyer; F Roudot-Thoraval; J L Cohen; C Cordonnier; F M Lemoine; D Klatzmann

doi:10.1038/leu.2014.237

Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study

Leukemia. 2014 Dec;28(12):2406-10. doi: 10.1038/leu.2014.237. Epub 2014 Aug 8.

Authors

S Maury¹, M Rosenzwajg², R Redjoul³, A Marcais⁴, A Xhaard⁵, M Cherai⁶, L Cabanne³, G Churlaud⁷, F Suarez⁴, G Socié⁵, L Gregoire⁸, K Debbache³, C Bernard⁹, J-L Beaumont¹⁰, N Azar⁷, O Boyer¹¹, F Roudot-Thoraval¹², J L Cohen¹³, C Cordonnier¹⁴, F M Lemoine¹⁵, D Klatzmann²

Affiliations

¹ 1] AP-HP, Hôpital Henri Mondor, Department of Hematology, DHU Virus-Immunity-Cancer, Créteil, France [2] IMRB, University Paris Est Créteil (UPEC), INSERM U955 team 21, Créteil, France [3] Center for Clinical Investigation in Biotherapy, Créteil, France.
² 1] AP-HP, Hôpital Pitié-Salpêtrière, Biotherapy Department, Paris, France [2] AP-HP, Hôpital Pitié-Salpêtrière, Clinical Investigation Center in Biotherapy (CIC-BTi), Paris, France [3] AP-HP, Hôpital Pitié-Salpêtrière, Inflammation-Immunopathology-Biotherapy Department (i2B), Paris, France [4] Sorbonne Université, UPMC Univ Paris 06, UMRS 959, Immunology-Immunopathology-Immunotherapy (I3), Paris, France [5] INSERM, UMR_S 959, Immunology-Immunopathology-Immunotherapy (I3), Paris, France.
³ AP-HP, Hôpital Henri Mondor, Department of Hematology, DHU Virus-Immunity-Cancer, Créteil, France.
⁴ Department of Hematology, Hôpital Necker, Paris, France.
⁵ Department of Hematology-Transplantation, Hôpital St Louis, Paris, France.
⁶ 1] AP-HP, Hôpital Pitié-Salpêtrière, Biotherapy Department, Paris, France [2] AP-HP, Hôpital Pitié-Salpêtrière, Clinical Investigation Center in Biotherapy (CIC-BTi), Paris, France.
⁷ AP-HP, Hôpital Pitié-Salpêtrière, Biotherapy Department, Paris, France.
⁸ Department of Public Health, Créteil, France.
⁹ 1] AP-HP, Hôpital Pitié-Salpêtrière, Biotherapy Department, Paris, France [2] AP-HP, Hôpital Pitié-Salpêtrière, Clinical Investigation Center in Biotherapy (CIC-BTi), Paris, France [3] AP-HP, Hôpital Pitié-Salpêtrière, Inflammation-Immunopathology-Biotherapy Department (i2B), Paris, France.
¹⁰ Department of Hemapheresis, Etablissement Français du Sang, Créteil, France.
¹¹ Sorbonne Universités, UPMC Univ Paris 06, UMR-S INSERM 1135, CIMI-Paris, Paris, France.
¹² 1] IMRB, University Paris Est Créteil (UPEC), INSERM U955 team 21, Créteil, France [2] Department of Public Health, Créteil, France.
¹³ 1] IMRB, University Paris Est Créteil (UPEC), INSERM U955 team 21, Créteil, France [2] Center for Clinical Investigation in Biotherapy, Créteil, France.
¹⁴ 1] AP-HP, Hôpital Henri Mondor, Department of Hematology, DHU Virus-Immunity-Cancer, Créteil, France [2] IMRB, University Paris Est Créteil (UPEC), INSERM U955 team 21, Créteil, France.
¹⁵ 1] AP-HP, Hôpital Pitié-Salpêtrière, Biotherapy Department, Paris, France [2] AP-HP, Hôpital Pitié-Salpêtrière, Clinical Investigation Center in Biotherapy (CIC-BTi), Paris, France [3] Sorbonne Universités, UPMC Univ Paris 06, UMR-S INSERM 1135, CIMI-Paris, Paris, France.

PMID: 25102947
DOI: 10.1038/leu.2014.237

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Letter

MeSH terms

Genes, Transgenic, Suicide*
Genetic Therapy*
Graft vs Host Disease / etiology
Humans
Immunotherapy, Adoptive* / adverse effects
Lymphocyte Depletion
Lymphocytes / immunology
Lymphocytes / metabolism*
Neoplasms / complications
Neoplasms / genetics*
Neoplasms / immunology
Neoplasms / therapy*
Tissue Donors
Transduction, Genetic
Treatment Outcome